Clinical Trials Logo
  1. Home
  2. Cardiovascular Diseases
  3. NCT00848380
  4. Details
NCT00848380 Clinical Trial

Management of Cardiovascular Risk Factors

Cardiovascular Diseases Clinical Trial

Official title:
Management of Cardiovascular Risk Factors

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00848380
Other study ID # NIS-CCH-DUM-2008/2
Secondary ID
Status Completed
Phase N/A
First received February 19, 2009
Last updated November 15, 2010
Start date February 2009
Est. completion date December 2009

Study information
Verified date November 2010
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority Switzerland: Ethikkommission
Study type Observational

Clinical Trial Summary

This practical experience should report a retrospective collection of data regarding cardiovascular risk factors of cardiovascular diseases. The goal is an evaluation of the development of the risk profile of cardiovascular patients with simultaneous treatment of hypertension and hyperlipidemia

Recruitment information / eligibility
Status Completed
Enrollment 1492
Est. completion date December 2009
Est. primary completion date December 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Patients received a anti-hypertension treatment in addition to cholesterol lowering treatment during the observation period

- Patients received a cholesterol lowering treatment in addition to hypertension treatment during the observation period

- Patients received during the observation time new cholesterol lowering and hypertension treatment

Exclusion Criteria:

- Patients received during the observation time only cholesterol lowering or only anti-hypertension treatment

Study Design

Observational Model: Case Control, Time Perspective: Retrospective

Related Conditions & MeSH terms

Locations
Country Name City State
Switzerland Research Site Affoltern am Albis ZH
Switzerland Research Site Andeer GR
Switzerland Research Site Arbedo TI
Switzerland Research Site Bassins VD
Switzerland Research Site Bellinzona TI
Switzerland Research Site Claro TI
Switzerland Research Site Coldrerio TI
Switzerland Research Site Feldmeilen ZH
Switzerland Research Site Frick AG
Switzerland Research Site Geneve GE
Switzerland Research Site Gerlafingen SO
Switzerland Research Site Gland VD
Switzerland Research Site Herrliberg ZH
Switzerland Research Site Ilanz GR
Switzerland Research Site Langnau am Albis ZH
Switzerland Research Site Lausanne VD
Switzerland Research Site Le Lignon GE
Switzerland Research Site Locarno TI
Switzerland Research Site Lohn SO SO
Switzerland Research Site Lugano TI
Switzerland Research Site Meyrin GE
Switzerland Research Site Montreux VD
Switzerland Research Site Muralto TI
Switzerland Research Site Neuenhof AG
Switzerland Research Site Nyon VD
Switzerland Research Site Richterswil ZH
Switzerland Research Site Riehen BS
Switzerland Research Site Rorschach SG
Switzerland Research Site Ruti ZH ZH
Switzerland Research Site Schwyz SZ
Switzerland Research Site St. Gallen SG
Switzerland Research Site Thun BE
Switzerland Research Site Wynigen BE
Switzerland Research Site Zuchwil SO
Switzerland Research Site Zug ZG
Switzerland Research Site Zurich ZH

Sponsors (1)
Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

Switzerland, 

Outcome
Type Measure Description Time frame Safety issue
Primary The goal is an evaluation of the development of the risk profile of cardiovascular patients with simultaneous treatment of hypertension and hyperlipidemia. Inclusion visit, 6 to 9 months before inclusion visit and / or 12 to 15 months before inclusion visit No
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)